nodes	percent_of_prediction	percent_of_DWPC	metapath
L-Carnitine—CES1—Capecitabine—colon cancer	0.364	0.489	CbGbCtD
L-Carnitine—CES1—Irinotecan—colon cancer	0.225	0.302	CbGbCtD
L-Carnitine—SLCO1B1—Irinotecan—colon cancer	0.0772	0.104	CbGbCtD
L-Carnitine—SLCO1B1—Methotrexate—colon cancer	0.0409	0.0549	CbGbCtD
L-Carnitine—SLC22A8—Methotrexate—colon cancer	0.0377	0.0507	CbGbCtD
L-Carnitine—MPO—superior mesenteric artery—colon cancer	0.033	0.231	CbGeAlD
L-Carnitine—CROT—Vinorelbine—Vincristine—colon cancer	0.00691	1	CbGdCrCtD
L-Carnitine—SLC22A16—renal system—colon cancer	0.00534	0.0372	CbGeAlD
L-Carnitine—SLC22A16—bone marrow—colon cancer	0.00403	0.0282	CbGeAlD
L-Carnitine—CROT—smooth muscle tissue—colon cancer	0.00401	0.028	CbGeAlD
L-Carnitine—CRAT—smooth muscle tissue—colon cancer	0.00338	0.0236	CbGeAlD
L-Carnitine—SLC25A20—renal system—colon cancer	0.00336	0.0234	CbGeAlD
L-Carnitine—CRAT—renal system—colon cancer	0.00326	0.0227	CbGeAlD
L-Carnitine—CES1—gall bladder—colon cancer	0.0031	0.0216	CbGeAlD
L-Carnitine—MPO—endothelium—colon cancer	0.00298	0.0208	CbGeAlD
L-Carnitine—CROT—bone marrow—colon cancer	0.00292	0.0204	CbGeAlD
L-Carnitine—CROT—vagina—colon cancer	0.00279	0.0195	CbGeAlD
L-Carnitine—MPO—blood vessel—colon cancer	0.00275	0.0192	CbGeAlD
L-Carnitine—CPT1A—renal system—colon cancer	0.00264	0.0184	CbGeAlD
L-Carnitine—SLC25A29—liver—colon cancer	0.00257	0.0179	CbGeAlD
L-Carnitine—SLC25A20—bone marrow—colon cancer	0.00254	0.0177	CbGeAlD
L-Carnitine—CPT2—renal system—colon cancer	0.0025	0.0175	CbGeAlD
L-Carnitine—CRAT—bone marrow—colon cancer	0.00246	0.0172	CbGeAlD
L-Carnitine—SLC25A20—vagina—colon cancer	0.00243	0.017	CbGeAlD
L-Carnitine—CRAT—vagina—colon cancer	0.00236	0.0165	CbGeAlD
L-Carnitine—CROT—liver—colon cancer	0.00236	0.0165	CbGeAlD
L-Carnitine—CPT1A—digestive system—colon cancer	0.00216	0.0151	CbGeAlD
L-Carnitine—SLC25A20—liver—colon cancer	0.00205	0.0143	CbGeAlD
L-Carnitine—CRAT—liver—colon cancer	0.00199	0.0139	CbGeAlD
L-Carnitine—SLC25A29—lymph node—colon cancer	0.00197	0.0138	CbGeAlD
L-Carnitine—XDH—renal system—colon cancer	0.00195	0.0136	CbGeAlD
L-Carnitine—Gastrointestinal symptom NOS—Fluorouracil—colon cancer	0.00192	0.0249	CcSEcCtD
L-Carnitine—CPT1A—vagina—colon cancer	0.00191	0.0133	CbGeAlD
L-Carnitine—CPT2—bone marrow—colon cancer	0.00189	0.0132	CbGeAlD
L-Carnitine—CPT2—vagina—colon cancer	0.00181	0.0127	CbGeAlD
L-Carnitine—CROT—lymph node—colon cancer	0.00181	0.0126	CbGeAlD
L-Carnitine—Abdominal cramps—Vincristine—colon cancer	0.00179	0.0232	CcSEcCtD
L-Carnitine—Abdominal cramps—Irinotecan—colon cancer	0.00174	0.0226	CcSEcCtD
L-Carnitine—CPT1A—liver—colon cancer	0.00161	0.0113	CbGeAlD
L-Carnitine—XDH—digestive system—colon cancer	0.0016	0.0112	CbGeAlD
L-Carnitine—SLC25A20—lymph node—colon cancer	0.00157	0.011	CbGeAlD
L-Carnitine—CPT2—liver—colon cancer	0.00153	0.0107	CbGeAlD
L-Carnitine—CRAT—lymph node—colon cancer	0.00153	0.0106	CbGeAlD
L-Carnitine—XDH—vagina—colon cancer	0.00141	0.00986	CbGeAlD
L-Carnitine—MPO—epithelium—colon cancer	0.00134	0.00935	CbGeAlD
L-Carnitine—Accidental injury—Irinotecan—colon cancer	0.00133	0.0173	CcSEcCtD
L-Carnitine—SLCO1B1—renal system—colon cancer	0.00128	0.00892	CbGeAlD
L-Carnitine—MPO—renal system—colon cancer	0.00124	0.00867	CbGeAlD
L-Carnitine—CPT1A—lymph node—colon cancer	0.00124	0.00863	CbGeAlD
L-Carnitine—CES1—lymphoid tissue—colon cancer	0.00123	0.00862	CbGeAlD
L-Carnitine—CES1—digestive system—colon cancer	0.00122	0.00851	CbGeAlD
L-Carnitine—XDH—liver—colon cancer	0.00119	0.00832	CbGeAlD
L-Carnitine—CPT1A—FOXA2 and FOXA3 transcription factor networks—HNF4A—colon cancer	0.00118	0.0411	CbGpPWpGaD
L-Carnitine—CPT2—lymph node—colon cancer	0.00117	0.00819	CbGeAlD
L-Carnitine—Hypercalcaemia—Capecitabine—colon cancer	0.00113	0.0147	CcSEcCtD
L-Carnitine—SLC22A4—renal system—colon cancer	0.00113	0.00792	CbGeAlD
L-Carnitine—CES1—Irinotecan Pathway—APC—colon cancer	0.00109	0.0377	CbGpPWpGaD
L-Carnitine—SLCO1B1—digestive system—colon cancer	0.00105	0.00732	CbGeAlD
L-Carnitine—MPO—lymphoid tissue—colon cancer	0.00103	0.0072	CbGeAlD
L-Carnitine—MPO—digestive system—colon cancer	0.00102	0.00711	CbGeAlD
L-Carnitine—SLCO1B1—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00101	0.035	CbGpPWpGaD
L-Carnitine—SLC22A8—renal system—colon cancer	0.000993	0.00693	CbGeAlD
L-Carnitine—MPO—bone marrow—colon cancer	0.000939	0.00655	CbGeAlD
L-Carnitine—SLC22A4—digestive system—colon cancer	0.00093	0.00649	CbGeAlD
L-Carnitine—Injury—Irinotecan—colon cancer	0.00093	0.0121	CcSEcCtD
L-Carnitine—CES1—liver—colon cancer	0.000909	0.00634	CbGeAlD
L-Carnitine—SLC22A4—bone marrow—colon cancer	0.000857	0.00599	CbGeAlD
L-Carnitine—CPT1A—AMPK Signaling—HNF4A—colon cancer	0.000826	0.0287	CbGpPWpGaD
L-Carnitine—SLC22A4—vagina—colon cancer	0.000821	0.00573	CbGeAlD
L-Carnitine—CPT2—PPAR Alpha Pathway—CCND1—colon cancer	0.000803	0.0279	CbGpPWpGaD
L-Carnitine—Injection site reaction—Capecitabine—colon cancer	0.000783	0.0102	CcSEcCtD
L-Carnitine—SLCO1B1—liver—colon cancer	0.000781	0.00545	CbGeAlD
L-Carnitine—Muscular weakness—Vincristine—colon cancer	0.000774	0.01	CcSEcCtD
L-Carnitine—Melaena—Capecitabine—colon cancer	0.00077	0.00998	CcSEcCtD
L-Carnitine—MPO—liver—colon cancer	0.000759	0.0053	CbGeAlD
L-Carnitine—SLC22A5—renal system—colon cancer	0.00075	0.00524	CbGeAlD
L-Carnitine—CES1—Fluoropyrimidine Activity—TYMS—colon cancer	0.000745	0.0259	CbGpPWpGaD
L-Carnitine—Muscular weakness—Fluorouracil—colon cancer	0.000722	0.00936	CcSEcCtD
L-Carnitine—CROT—Metabolism—CA7—colon cancer	0.000698	0.0243	CbGpPWpGaD
L-Carnitine—CES1—lymph node—colon cancer	0.000697	0.00486	CbGeAlD
L-Carnitine—Weight decreased—Vincristine—colon cancer	0.000686	0.0089	CcSEcCtD
L-Carnitine—Depression—Vincristine—colon cancer	0.000674	0.00874	CcSEcCtD
L-Carnitine—Weight decreased—Irinotecan—colon cancer	0.000668	0.00866	CcSEcCtD
L-Carnitine—Renal failure—Irinotecan—colon cancer	0.000647	0.00839	CcSEcCtD
L-Carnitine—CPT2—PPAR Alpha Pathway—MYC—colon cancer	0.000644	0.0224	CbGpPWpGaD
L-Carnitine—SLC22A5—digestive system—colon cancer	0.000616	0.0043	CbGeAlD
L-Carnitine—Urinary tract infection—Fluorouracil—colon cancer	0.000613	0.00795	CcSEcCtD
L-Carnitine—CPT1A—Circadian rythm related genes—TOP1—colon cancer	0.000612	0.0212	CbGpPWpGaD
L-Carnitine—Atrial fibrillation—Capecitabine—colon cancer	0.000604	0.00783	CcSEcCtD
L-Carnitine—Haemoglobin—Irinotecan—colon cancer	0.000594	0.00771	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—CA7—colon cancer	0.000594	0.0206	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—CA7—colon cancer	0.000594	0.0206	CbGpPWpGaD
L-Carnitine—Rhinitis—Irinotecan—colon cancer	0.000593	0.00769	CcSEcCtD
L-Carnitine—Sinusitis—Fluorouracil—colon cancer	0.000592	0.00767	CcSEcCtD
L-Carnitine—Haemorrhage—Irinotecan—colon cancer	0.000591	0.00767	CcSEcCtD
L-Carnitine—MPO—lymph node—colon cancer	0.000582	0.00406	CbGeAlD
L-Carnitine—Melaena—Methotrexate—colon cancer	0.000573	0.00743	CcSEcCtD
L-Carnitine—Haemoglobin—Fluorouracil—colon cancer	0.000569	0.00738	CcSEcCtD
L-Carnitine—Rhinitis—Fluorouracil—colon cancer	0.000568	0.00736	CcSEcCtD
L-Carnitine—Haemorrhage—Fluorouracil—colon cancer	0.000566	0.00734	CcSEcCtD
L-Carnitine—Pharyngitis—Fluorouracil—colon cancer	0.000562	0.00729	CcSEcCtD
L-Carnitine—CPT1A—PPAR Alpha Pathway—CCND1—colon cancer	0.000557	0.0193	CbGpPWpGaD
L-Carnitine—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000551	0.0192	CbGpPWpGaD
L-Carnitine—Angiopathy—Vincristine—colon cancer	0.000551	0.00714	CcSEcCtD
L-Carnitine—SLC22A5—vagina—colon cancer	0.000544	0.00379	CbGeAlD
L-Carnitine—Angiopathy—Irinotecan—colon cancer	0.000536	0.00696	CcSEcCtD
L-Carnitine—SLC22A4—lymph node—colon cancer	0.000531	0.00371	CbGeAlD
L-Carnitine—CPT1A—RORA activates circadian gene expression—EP300—colon cancer	0.000529	0.0184	CbGpPWpGaD
L-Carnitine—Arrhythmia—Irinotecan—colon cancer	0.000528	0.00685	CcSEcCtD
L-Carnitine—Back pain—Vincristine—colon cancer	0.000511	0.00663	CcSEcCtD
L-Carnitine—Gastritis—Capecitabine—colon cancer	0.000506	0.00656	CcSEcCtD
L-Carnitine—Arrhythmia—Fluorouracil—colon cancer	0.000506	0.00656	CcSEcCtD
L-Carnitine—Muscular weakness—Capecitabine—colon cancer	0.000505	0.00654	CcSEcCtD
L-Carnitine—Back pain—Irinotecan—colon cancer	0.000498	0.00646	CcSEcCtD
L-Carnitine—Muscle spasms—Irinotecan—colon cancer	0.000495	0.00642	CcSEcCtD
L-Carnitine—Influenza—Capecitabine—colon cancer	0.000494	0.00641	CcSEcCtD
L-Carnitine—Anaemia—Vincristine—colon cancer	0.000489	0.00633	CcSEcCtD
L-Carnitine—Anaemia—Irinotecan—colon cancer	0.000476	0.00617	CcSEcCtD
L-Carnitine—Bronchitis—Capecitabine—colon cancer	0.000475	0.00616	CcSEcCtD
L-Carnitine—Vertigo—Vincristine—colon cancer	0.000475	0.00616	CcSEcCtD
L-Carnitine—SLCO1B1—Irinotecan Pathway—APC—colon cancer	0.000464	0.0161	CbGpPWpGaD
L-Carnitine—Vertigo—Irinotecan—colon cancer	0.000462	0.006	CcSEcCtD
L-Carnitine—SLC22A5—liver—colon cancer	0.000459	0.0032	CbGeAlD
L-Carnitine—Convulsion—Vincristine—colon cancer	0.000458	0.00594	CcSEcCtD
L-Carnitine—Hypertension—Vincristine—colon cancer	0.000456	0.00592	CcSEcCtD
L-Carnitine—Anaemia—Fluorouracil—colon cancer	0.000456	0.00591	CcSEcCtD
L-Carnitine—Myalgia—Vincristine—colon cancer	0.00045	0.00583	CcSEcCtD
L-Carnitine—Weight increased—Capecitabine—colon cancer	0.00045	0.00583	CcSEcCtD
L-Carnitine—Cough—Irinotecan—colon cancer	0.000449	0.00582	CcSEcCtD
L-Carnitine—Weight decreased—Capecitabine—colon cancer	0.000447	0.0058	CcSEcCtD
L-Carnitine—CPT1A—PPAR Alpha Pathway—MYC—colon cancer	0.000447	0.0155	CbGpPWpGaD
L-Carnitine—Hypertension—Irinotecan—colon cancer	0.000444	0.00576	CcSEcCtD
L-Carnitine—Depression—Capecitabine—colon cancer	0.00044	0.0057	CcSEcCtD
L-Carnitine—Renal failure—Capecitabine—colon cancer	0.000433	0.00562	CcSEcCtD
L-Carnitine—Infection—Vincristine—colon cancer	0.000429	0.00556	CcSEcCtD
L-Carnitine—Urinary tract infection—Capecitabine—colon cancer	0.000429	0.00556	CcSEcCtD
L-Carnitine—Convulsion—Fluorouracil—colon cancer	0.000427	0.00554	CcSEcCtD
L-Carnitine—CROT—Metabolism—CHST5—colon cancer	0.000423	0.0147	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—ODC1—colon cancer	0.000423	0.0147	CbGpPWpGaD
L-Carnitine—Chest pain—Fluorouracil—colon cancer	0.00042	0.00544	CcSEcCtD
L-Carnitine—Myalgia—Fluorouracil—colon cancer	0.00042	0.00544	CcSEcCtD
L-Carnitine—Infection—Irinotecan—colon cancer	0.000417	0.00541	CcSEcCtD
L-Carnitine—Anorexia—Vincristine—colon cancer	0.000411	0.00533	CcSEcCtD
L-Carnitine—Hypotension—Vincristine—colon cancer	0.000403	0.00523	CcSEcCtD
L-Carnitine—Anorexia—Irinotecan—colon cancer	0.0004	0.00519	CcSEcCtD
L-Carnitine—Infection—Fluorouracil—colon cancer	0.0004	0.00518	CcSEcCtD
L-Carnitine—Haemoglobin—Capecitabine—colon cancer	0.000398	0.00516	CcSEcCtD
L-Carnitine—Rhinitis—Capecitabine—colon cancer	0.000397	0.00514	CcSEcCtD
L-Carnitine—Haemorrhage—Capecitabine—colon cancer	0.000396	0.00513	CcSEcCtD
L-Carnitine—CES1—E2F transcription factor network—TYMS—colon cancer	0.000395	0.0137	CbGpPWpGaD
L-Carnitine—Musculoskeletal discomfort—Vincristine—colon cancer	0.000393	0.0051	CcSEcCtD
L-Carnitine—Pharyngitis—Capecitabine—colon cancer	0.000393	0.00509	CcSEcCtD
L-Carnitine—Tachycardia—Fluorouracil—colon cancer	0.000393	0.00509	CcSEcCtD
L-Carnitine—Hypotension—Irinotecan—colon cancer	0.000393	0.00509	CcSEcCtD
L-Carnitine—Insomnia—Vincristine—colon cancer	0.00039	0.00506	CcSEcCtD
L-Carnitine—Oedema peripheral—Capecitabine—colon cancer	0.00039	0.00505	CcSEcCtD
L-Carnitine—Paraesthesia—Vincristine—colon cancer	0.000387	0.00502	CcSEcCtD
L-Carnitine—Anorexia—Fluorouracil—colon cancer	0.000384	0.00497	CcSEcCtD
L-Carnitine—CPT2—Metabolism—CA7—colon cancer	0.000383	0.0133	CbGpPWpGaD
L-Carnitine—Insomnia—Irinotecan—colon cancer	0.00038	0.00493	CcSEcCtD
L-Carnitine—Paraesthesia—Irinotecan—colon cancer	0.000377	0.00489	CcSEcCtD
L-Carnitine—Hypotension—Fluorouracil—colon cancer	0.000376	0.00487	CcSEcCtD
L-Carnitine—Decreased appetite—Vincristine—colon cancer	0.000375	0.00486	CcSEcCtD
L-Carnitine—Dyspnoea—Irinotecan—colon cancer	0.000375	0.00486	CcSEcCtD
L-Carnitine—SLC25A20—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000373	0.013	CbGpPWpGaD
L-Carnitine—Gastrointestinal disorder—Vincristine—colon cancer	0.000372	0.00483	CcSEcCtD
L-Carnitine—Eye disorder—Capecitabine—colon cancer	0.00037	0.00479	CcSEcCtD
L-Carnitine—Dyspepsia—Irinotecan—colon cancer	0.00037	0.00479	CcSEcCtD
L-Carnitine—Constipation—Vincristine—colon cancer	0.000369	0.00478	CcSEcCtD
L-Carnitine—Pain—Vincristine—colon cancer	0.000369	0.00478	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000367	0.00475	CcSEcCtD
L-Carnitine—Decreased appetite—Irinotecan—colon cancer	0.000365	0.00473	CcSEcCtD
L-Carnitine—Insomnia—Fluorouracil—colon cancer	0.000364	0.00472	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Irinotecan—colon cancer	0.000363	0.0047	CcSEcCtD
L-Carnitine—Paraesthesia—Fluorouracil—colon cancer	0.000361	0.00468	CcSEcCtD
L-Carnitine—CRAT—Metabolism—CHST5—colon cancer	0.00036	0.0125	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—ODC1—colon cancer	0.00036	0.0125	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—ODC1—colon cancer	0.00036	0.0125	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—CHST5—colon cancer	0.00036	0.0125	CbGpPWpGaD
L-Carnitine—Constipation—Irinotecan—colon cancer	0.000359	0.00466	CcSEcCtD
L-Carnitine—Pain—Irinotecan—colon cancer	0.000359	0.00466	CcSEcCtD
L-Carnitine—Angiopathy—Capecitabine—colon cancer	0.000359	0.00466	CcSEcCtD
L-Carnitine—Dyspnoea—Fluorouracil—colon cancer	0.000359	0.00465	CcSEcCtD
L-Carnitine—CPT2—PPARA activates gene expression—PPARG—colon cancer	0.000356	0.0124	CbGpPWpGaD
L-Carnitine—Dyspepsia—Fluorouracil—colon cancer	0.000354	0.00459	CcSEcCtD
L-Carnitine—Arrhythmia—Capecitabine—colon cancer	0.000354	0.00458	CcSEcCtD
L-Carnitine—Gastrointestinal pain—Vincristine—colon cancer	0.000353	0.00457	CcSEcCtD
L-Carnitine—SLC22A5—lymph node—colon cancer	0.000352	0.00245	CbGeAlD
L-Carnitine—Decreased appetite—Fluorouracil—colon cancer	0.00035	0.00453	CcSEcCtD
L-Carnitine—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.000349	0.0121	CbGpPWpGaD
L-Carnitine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000347	0.0045	CcSEcCtD
L-Carnitine—Pain—Fluorouracil—colon cancer	0.000344	0.00446	CcSEcCtD
L-Carnitine—Gastrointestinal pain—Irinotecan—colon cancer	0.000344	0.00445	CcSEcCtD
L-Carnitine—Body temperature increased—Vincristine—colon cancer	0.000341	0.00442	CcSEcCtD
L-Carnitine—Abdominal pain—Vincristine—colon cancer	0.000341	0.00442	CcSEcCtD
L-Carnitine—Dysgeusia—Capecitabine—colon cancer	0.000337	0.00437	CcSEcCtD
L-Carnitine—Back pain—Capecitabine—colon cancer	0.000333	0.00432	CcSEcCtD
L-Carnitine—Abdominal pain—Irinotecan—colon cancer	0.000332	0.00431	CcSEcCtD
L-Carnitine—Body temperature increased—Irinotecan—colon cancer	0.000332	0.00431	CcSEcCtD
L-Carnitine—Muscle spasms—Capecitabine—colon cancer	0.000331	0.00429	CcSEcCtD
L-Carnitine—Depression—Methotrexate—colon cancer	0.000327	0.00424	CcSEcCtD
L-Carnitine—Renal failure—Methotrexate—colon cancer	0.000323	0.00418	CcSEcCtD
L-Carnitine—Anaemia—Capecitabine—colon cancer	0.000318	0.00413	CcSEcCtD
L-Carnitine—Body temperature increased—Fluorouracil—colon cancer	0.000318	0.00412	CcSEcCtD
L-Carnitine—Hypersensitivity—Vincristine—colon cancer	0.000318	0.00412	CcSEcCtD
L-Carnitine—Vertigo—Capecitabine—colon cancer	0.00031	0.00401	CcSEcCtD
L-Carnitine—Hypersensitivity—Irinotecan—colon cancer	0.00031	0.00401	CcSEcCtD
L-Carnitine—Asthenia—Vincristine—colon cancer	0.000309	0.00401	CcSEcCtD
L-Carnitine—Palpitations—Capecitabine—colon cancer	0.000304	0.00395	CcSEcCtD
L-Carnitine—XDH—Nucleotide metabolism—TYMS—colon cancer	0.000304	0.0106	CbGpPWpGaD
L-Carnitine—Asthenia—Irinotecan—colon cancer	0.000301	0.00391	CcSEcCtD
L-Carnitine—Cough—Capecitabine—colon cancer	0.000301	0.0039	CcSEcCtD
L-Carnitine—Hypertension—Capecitabine—colon cancer	0.000297	0.00386	CcSEcCtD
L-Carnitine—Hypersensitivity—Fluorouracil—colon cancer	0.000296	0.00384	CcSEcCtD
L-Carnitine—Haemoglobin—Methotrexate—colon cancer	0.000296	0.00384	CcSEcCtD
L-Carnitine—Diarrhoea—Vincristine—colon cancer	0.000295	0.00383	CcSEcCtD
L-Carnitine—Haemorrhage—Methotrexate—colon cancer	0.000295	0.00382	CcSEcCtD
L-Carnitine—Chest pain—Capecitabine—colon cancer	0.000293	0.0038	CcSEcCtD
L-Carnitine—Myalgia—Capecitabine—colon cancer	0.000293	0.0038	CcSEcCtD
L-Carnitine—Pharyngitis—Methotrexate—colon cancer	0.000292	0.00379	CcSEcCtD
L-Carnitine—Anxiety—Capecitabine—colon cancer	0.000292	0.00379	CcSEcCtD
L-Carnitine—Diarrhoea—Irinotecan—colon cancer	0.000287	0.00373	CcSEcCtD
L-Carnitine—Dizziness—Vincristine—colon cancer	0.000285	0.0037	CcSEcCtD
L-Carnitine—Pruritus—Fluorouracil—colon cancer	0.000285	0.00369	CcSEcCtD
L-Carnitine—CPT1A—Circadian Clock—EP300—colon cancer	0.000281	0.00978	CbGpPWpGaD
L-Carnitine—Infection—Capecitabine—colon cancer	0.000279	0.00362	CcSEcCtD
L-Carnitine—Dizziness—Irinotecan—colon cancer	0.000278	0.0036	CcSEcCtD
L-Carnitine—Eye disorder—Methotrexate—colon cancer	0.000275	0.00357	CcSEcCtD
L-Carnitine—Diarrhoea—Fluorouracil—colon cancer	0.000275	0.00357	CcSEcCtD
L-Carnitine—Tachycardia—Capecitabine—colon cancer	0.000274	0.00356	CcSEcCtD
L-Carnitine—Vomiting—Vincristine—colon cancer	0.000274	0.00356	CcSEcCtD
L-Carnitine—Rash—Vincristine—colon cancer	0.000272	0.00353	CcSEcCtD
L-Carnitine—Dermatitis—Vincristine—colon cancer	0.000272	0.00352	CcSEcCtD
L-Carnitine—Headache—Vincristine—colon cancer	0.00027	0.0035	CcSEcCtD
L-Carnitine—Anorexia—Capecitabine—colon cancer	0.000268	0.00347	CcSEcCtD
L-Carnitine—Angiopathy—Methotrexate—colon cancer	0.000267	0.00347	CcSEcCtD
L-Carnitine—Vomiting—Irinotecan—colon cancer	0.000267	0.00346	CcSEcCtD
L-Carnitine—Dizziness—Fluorouracil—colon cancer	0.000266	0.00345	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—CA7—colon cancer	0.000265	0.00922	CbGpPWpGaD
L-Carnitine—Rash—Irinotecan—colon cancer	0.000265	0.00343	CcSEcCtD
L-Carnitine—Dermatitis—Irinotecan—colon cancer	0.000265	0.00343	CcSEcCtD
L-Carnitine—Headache—Irinotecan—colon cancer	0.000263	0.00341	CcSEcCtD
L-Carnitine—Hypotension—Capecitabine—colon cancer	0.000263	0.00341	CcSEcCtD
L-Carnitine—Nausea—Vincristine—colon cancer	0.000256	0.00332	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000256	0.00332	CcSEcCtD
L-Carnitine—Vomiting—Fluorouracil—colon cancer	0.000256	0.00332	CcSEcCtD
L-Carnitine—Insomnia—Capecitabine—colon cancer	0.000254	0.0033	CcSEcCtD
L-Carnitine—Rash—Fluorouracil—colon cancer	0.000254	0.00329	CcSEcCtD
L-Carnitine—Dermatitis—Fluorouracil—colon cancer	0.000253	0.00329	CcSEcCtD
L-Carnitine—Paraesthesia—Capecitabine—colon cancer	0.000252	0.00327	CcSEcCtD
L-Carnitine—Headache—Fluorouracil—colon cancer	0.000252	0.00327	CcSEcCtD
L-Carnitine—Dysgeusia—Methotrexate—colon cancer	0.000251	0.00326	CcSEcCtD
L-Carnitine—Dyspnoea—Capecitabine—colon cancer	0.000251	0.00325	CcSEcCtD
L-Carnitine—Nausea—Irinotecan—colon cancer	0.00025	0.00324	CcSEcCtD
L-Carnitine—Back pain—Methotrexate—colon cancer	0.000248	0.00322	CcSEcCtD
L-Carnitine—Dyspepsia—Capecitabine—colon cancer	0.000247	0.00321	CcSEcCtD
L-Carnitine—CES1—Fluoropyrimidine Activity—TP53—colon cancer	0.000247	0.00858	CbGpPWpGaD
L-Carnitine—CPT1A—PPARA activates gene expression—PPARG—colon cancer	0.000247	0.00858	CbGpPWpGaD
L-Carnitine—CPT1A—AMPK Signaling—CDKN1A—colon cancer	0.000247	0.00857	CbGpPWpGaD
L-Carnitine—Decreased appetite—Capecitabine—colon cancer	0.000244	0.00317	CcSEcCtD
L-Carnitine—SLC25A20—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000244	0.00848	CbGpPWpGaD
L-Carnitine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000243	0.00315	CcSEcCtD
L-Carnitine—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.000242	0.0084	CbGpPWpGaD
L-Carnitine—Constipation—Capecitabine—colon cancer	0.00024	0.00312	CcSEcCtD
L-Carnitine—Pain—Capecitabine—colon cancer	0.00024	0.00312	CcSEcCtD
L-Carnitine—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.00024	0.00835	CbGpPWpGaD
L-Carnitine—Nausea—Fluorouracil—colon cancer	0.000239	0.0031	CcSEcCtD
L-Carnitine—Anaemia—Methotrexate—colon cancer	0.000237	0.00307	CcSEcCtD
L-Carnitine—CPT2—PPARA activates gene expression—EP300—colon cancer	0.000233	0.0081	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—CHST5—colon cancer	0.000232	0.00805	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—ODC1—colon cancer	0.000232	0.00805	CbGpPWpGaD
L-Carnitine—Vertigo—Methotrexate—colon cancer	0.00023	0.00299	CcSEcCtD
L-Carnitine—Gastrointestinal pain—Capecitabine—colon cancer	0.00023	0.00298	CcSEcCtD
L-Carnitine—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.000228	0.00793	CbGpPWpGaD
L-Carnitine—Cough—Methotrexate—colon cancer	0.000224	0.0029	CcSEcCtD
L-Carnitine—Abdominal pain—Capecitabine—colon cancer	0.000222	0.00288	CcSEcCtD
L-Carnitine—Body temperature increased—Capecitabine—colon cancer	0.000222	0.00288	CcSEcCtD
L-Carnitine—Convulsion—Methotrexate—colon cancer	0.000222	0.00288	CcSEcCtD
L-Carnitine—Chest pain—Methotrexate—colon cancer	0.000218	0.00283	CcSEcCtD
L-Carnitine—Myalgia—Methotrexate—colon cancer	0.000218	0.00283	CcSEcCtD
L-Carnitine—MPO—IL23-mediated signaling events—PIK3CA—colon cancer	0.000217	0.00753	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—TYMS—colon cancer	0.000215	0.00748	CbGpPWpGaD
L-Carnitine—Infection—Methotrexate—colon cancer	0.000208	0.0027	CcSEcCtD
L-Carnitine—Hypersensitivity—Capecitabine—colon cancer	0.000207	0.00269	CcSEcCtD
L-Carnitine—CPT1A—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	0.000203	0.00706	CbGpPWpGaD
L-Carnitine—Asthenia—Capecitabine—colon cancer	0.000202	0.00262	CcSEcCtD
L-Carnitine—Anorexia—Methotrexate—colon cancer	0.0002	0.00259	CcSEcCtD
L-Carnitine—Pruritus—Capecitabine—colon cancer	0.000199	0.00258	CcSEcCtD
L-Carnitine—Hypotension—Methotrexate—colon cancer	0.000196	0.00254	CcSEcCtD
L-Carnitine—Diarrhoea—Capecitabine—colon cancer	0.000192	0.00249	CcSEcCtD
L-Carnitine—CES1—E2F transcription factor network—CDKN1A—colon cancer	0.000192	0.00668	CbGpPWpGaD
L-Carnitine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000191	0.00247	CcSEcCtD
L-Carnitine—Insomnia—Methotrexate—colon cancer	0.000189	0.00245	CcSEcCtD
L-Carnitine—Paraesthesia—Methotrexate—colon cancer	0.000188	0.00244	CcSEcCtD
L-Carnitine—Dyspnoea—Methotrexate—colon cancer	0.000187	0.00242	CcSEcCtD
L-Carnitine—Dizziness—Capecitabine—colon cancer	0.000186	0.00241	CcSEcCtD
L-Carnitine—Dyspepsia—Methotrexate—colon cancer	0.000184	0.00239	CcSEcCtD
L-Carnitine—CES1—E2F transcription factor network—EP300—colon cancer	0.000183	0.00635	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—PTGS2—colon cancer	0.000183	0.00635	CbGpPWpGaD
L-Carnitine—Decreased appetite—Methotrexate—colon cancer	0.000182	0.00236	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Methotrexate—colon cancer	0.000181	0.00234	CcSEcCtD
L-Carnitine—Pain—Methotrexate—colon cancer	0.000179	0.00232	CcSEcCtD
L-Carnitine—Vomiting—Capecitabine—colon cancer	0.000179	0.00232	CcSEcCtD
L-Carnitine—Rash—Capecitabine—colon cancer	0.000177	0.0023	CcSEcCtD
L-Carnitine—Dermatitis—Capecitabine—colon cancer	0.000177	0.0023	CcSEcCtD
L-Carnitine—Headache—Capecitabine—colon cancer	0.000176	0.00228	CcSEcCtD
L-Carnitine—MPO—Selenium Micronutrient Network—PTGS2—colon cancer	0.000176	0.00612	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—CA7—colon cancer	0.000176	0.0061	CbGpPWpGaD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000175	0.00607	CbGpPWpGaD
L-Carnitine—CPT1A—AMPK Signaling—PIK3CA—colon cancer	0.000174	0.00603	CbGpPWpGaD
L-Carnitine—Gastrointestinal pain—Methotrexate—colon cancer	0.000171	0.00222	CcSEcCtD
L-Carnitine—CPT1A—AMPK Signaling—TP53—colon cancer	0.000168	0.00584	CbGpPWpGaD
L-Carnitine—Nausea—Capecitabine—colon cancer	0.000167	0.00217	CcSEcCtD
L-Carnitine—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000167	0.00579	CbGpPWpGaD
L-Carnitine—SLC22A16—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000165	0.00575	CbGpPWpGaD
L-Carnitine—Abdominal pain—Methotrexate—colon cancer	0.000165	0.00215	CcSEcCtD
L-Carnitine—Body temperature increased—Methotrexate—colon cancer	0.000165	0.00215	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—CCND1—colon cancer	0.000165	0.00574	CbGpPWpGaD
L-Carnitine—CPT1A—PPARA activates gene expression—EP300—colon cancer	0.000162	0.00562	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—ODC1—colon cancer	0.000161	0.00558	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—CHST5—colon cancer	0.000161	0.00558	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—CDKN1A—colon cancer	0.00016	0.00555	CbGpPWpGaD
L-Carnitine—CES1—E2F transcription factor network—MYC—colon cancer	0.000159	0.00554	CbGpPWpGaD
L-Carnitine—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.000158	0.0055	CbGpPWpGaD
L-Carnitine—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000157	0.00546	CbGpPWpGaD
L-Carnitine—Hypersensitivity—Methotrexate—colon cancer	0.000154	0.002	CcSEcCtD
L-Carnitine—XDH—Selenium Micronutrient Network—PTGS2—colon cancer	0.000154	0.00535	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—PPARG—colon cancer	0.000153	0.0053	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—EP300—colon cancer	0.000152	0.00528	CbGpPWpGaD
L-Carnitine—Asthenia—Methotrexate—colon cancer	0.00015	0.00195	CcSEcCtD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000149	0.00516	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000149	0.00516	CbGpPWpGaD
L-Carnitine—Pruritus—Methotrexate—colon cancer	0.000148	0.00192	CcSEcCtD
L-Carnitine—Diarrhoea—Methotrexate—colon cancer	0.000143	0.00186	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—NRAS—colon cancer	0.000142	0.00494	CbGpPWpGaD
L-Carnitine—CPT1A—AMPK Signaling—AKT1—colon cancer	0.000142	0.00493	CbGpPWpGaD
L-Carnitine—Dizziness—Methotrexate—colon cancer	0.000138	0.00179	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000137	0.00477	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000136	0.00474	CbGpPWpGaD
L-Carnitine—Vomiting—Methotrexate—colon cancer	0.000133	0.00173	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—MYC—colon cancer	0.000132	0.0046	CbGpPWpGaD
L-Carnitine—Rash—Methotrexate—colon cancer	0.000132	0.00171	CcSEcCtD
L-Carnitine—MPO—Folate Metabolism—TP53—colon cancer	0.000132	0.00458	CbGpPWpGaD
L-Carnitine—Dermatitis—Methotrexate—colon cancer	0.000132	0.00171	CcSEcCtD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000131	0.00457	CbGpPWpGaD
L-Carnitine—Headache—Methotrexate—colon cancer	0.000131	0.0017	CcSEcCtD
L-Carnitine—Nausea—Methotrexate—colon cancer	0.000124	0.00161	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—KRAS—colon cancer	0.000122	0.00425	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—EP300—colon cancer	0.000122	0.00425	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000117	0.00406	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000117	0.00406	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000116	0.00402	CbGpPWpGaD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000114	0.00397	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—ABCB1—colon cancer	0.000112	0.00388	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—TYMS—colon cancer	0.00011	0.00382	CbGpPWpGaD
L-Carnitine—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000109	0.00379	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—ODC1—colon cancer	0.000106	0.0037	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—CHST5—colon cancer	0.000106	0.0037	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—HRAS—colon cancer	0.000104	0.00361	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—EP300—colon cancer	9.98e-05	0.00347	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.72e-05	0.00338	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.72e-05	0.00338	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	9.57e-05	0.00333	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—ABCB1—colon cancer	9.51e-05	0.0033	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—ABCB1—colon cancer	9.51e-05	0.0033	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—TYMS—colon cancer	9.34e-05	0.00324	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—TYMS—colon cancer	9.34e-05	0.00324	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—CA7—colon cancer	9.25e-05	0.00321	CbGpPWpGaD
L-Carnitine—CES1—NRF2 pathway—TGFB1—colon cancer	9.13e-05	0.00317	CbGpPWpGaD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.45e-05	0.00294	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PPARG—colon cancer	7.78e-05	0.0027	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	7.53e-05	0.00262	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.19e-05	0.0025	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.19e-05	0.0025	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—TP53—colon cancer	7.14e-05	0.00248	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PPARG—colon cancer	6.63e-05	0.0023	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PPARG—colon cancer	6.61e-05	0.0023	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PPARG—colon cancer	6.61e-05	0.0023	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.26e-05	0.00218	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—ABCB1—colon cancer	6.13e-05	0.00213	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—ABCB1—colon cancer	6.12e-05	0.00213	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PTGS2—colon cancer	6.12e-05	0.00213	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—TYMS—colon cancer	6.02e-05	0.00209	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—CHST5—colon cancer	5.6e-05	0.00195	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—ODC1—colon cancer	5.6e-05	0.00195	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.22e-05	0.00181	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PTGS2—colon cancer	5.2e-05	0.00181	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PTGS2—colon cancer	5.2e-05	0.00181	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—EP300—colon cancer	5.09e-05	0.00177	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.63e-05	0.00161	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—ABCB1—colon cancer	4.6e-05	0.0016	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.34e-05	0.00151	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—EP300—colon cancer	4.33e-05	0.0015	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—EP300—colon cancer	4.33e-05	0.0015	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PPARG—colon cancer	4.26e-05	0.00148	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—ABCB1—colon cancer	4.25e-05	0.00148	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—TYMS—colon cancer	4.17e-05	0.00145	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—ABCB1—colon cancer	4.16e-05	0.00145	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PIK3CA—colon cancer	3.76e-05	0.00131	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PTGS2—colon cancer	3.35e-05	0.00116	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.21e-05	0.00112	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PIK3CA—colon cancer	3.2e-05	0.00111	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PIK3CA—colon cancer	3.2e-05	0.00111	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—ABCB1—colon cancer	3.16e-05	0.0011	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—AKT1—colon cancer	3.08e-05	0.00107	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PPARG—colon cancer	2.95e-05	0.00103	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—ABCB1—colon cancer	2.81e-05	0.000977	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—EP300—colon cancer	2.79e-05	0.000969	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—TYMS—colon cancer	2.76e-05	0.00096	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—AKT1—colon cancer	2.62e-05	0.000909	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—AKT1—colon cancer	2.62e-05	0.000909	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PTGS2—colon cancer	2.32e-05	0.000807	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.31e-05	0.000804	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PIK3CA—colon cancer	2.06e-05	0.000717	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PPARG—colon cancer	1.96e-05	0.00068	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—EP300—colon cancer	1.93e-05	0.000672	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.82e-05	0.000632	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—AKT1—colon cancer	1.69e-05	0.000585	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PTGS2—colon cancer	1.54e-05	0.000535	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.51e-05	0.000526	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—ABCB1—colon cancer	1.48e-05	0.000514	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—TYMS—colon cancer	1.45e-05	0.000505	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PIK3CA—colon cancer	1.43e-05	0.000497	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—EP300—colon cancer	1.28e-05	0.000445	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—AKT1—colon cancer	1.17e-05	0.000406	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.12e-05	0.000389	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PPARG—colon cancer	1.03e-05	0.000358	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PIK3CA—colon cancer	9.47e-06	0.000329	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PTGS2—colon cancer	8.1e-06	0.000282	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—AKT1—colon cancer	7.74e-06	0.000269	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—EP300—colon cancer	6.74e-06	0.000234	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PIK3CA—colon cancer	4.98e-06	0.000173	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—AKT1—colon cancer	4.07e-06	0.000141	CbGpPWpGaD
